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Abstract
Background: Transmitted drug resistance (TDR) is an important public health issue, because TDR-associated
mutation may affect the outcome of antiretroviral treatment potentially or directly. Men who have sex with men
(MSM) constitute a major risk group for HIV transmission. However, current reports are scarce on HIV TDR-associated
mutations and their co-variation among MSM.
Methods: Blood samples from 262 newly diagnosed HIV-positive, antiretroviral therapy (ART)-naïve MSM, were
collected from January 2011 and December 2013 in Beijing. The polymerase viral genes were sequenced to explore
TDR-associated mutations and mutation co-variation.
Results: A total of 223 samples were sequenced and analyzed. Among them, HIV-1 CRF01_AE are accounted for 60.5%,
followed by CRF07_BC (27.8%), subtype B (9.9%), and others. Fifty-seven samples had at least one TDR-associated
mutation, mainly including L10I/V (6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I (2.7%), with different distributions
of TDR-associated mutations by different HIV-1 subtypes and by each year. Moreover, eight significant co-variation pairs
were found between TDR-associated mutations (V179D/E) and seven overlapping polymorphisms in subtype
CRF01_AE.
Conclusions: To date, this work consists the most comprehensive genetic characterization of HIV-1 TDR-associated
mutations prevalent among MSM. It provides important information for understanding TDR and viral evolution among
Chinese MSM, a population currently at particularly high risk of HIV transmission.
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Background
The increasing availability of antiretroviral therapy (ART)
worldwide has significantly reduced mortality and im-
proved quality of life for HIV-infected patients. However,
the therapeutic effect of ART is weakened by the emer-
gence of drug-resistant mutant viruses. Transmission of
drug-resistant (TDR) strains to persons who are ART-
naïve can compromise the effectiveness of treatment and
limit antiretroviral regimens options. TDR consists 10 ~
20% of new HIV-1 infections worldwide [1]. In resource-
limited countries such as China, where ART is provided to
patients for free through the “Four Free One Care” policy
[2], TDR against standard ART regimens threatens the
stability of treatment programs and must be carefully
monitored.
Several factors contribute to the occurrence of TDR, in-
cluding frequency of exposure to non-treatment naïve vi-
ruses, ART regimen efficacy in the transmitting patient,
rates of virologic suppression, and genetic diversity and
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replicative capacity of the viral strains in question. To our
interest, evidence suggests that HIV-1 genetic diversity
may influence the type and rate of resistance mutations
that may eventually emerge upon drug exposure [3,4]. Pre-
vious studies showed a significant correlation between
treatment-associated mutations and overlapping polymor-
phisms in the RT and PR viral genes [5]. We postulate that
there may be co-variation between TDR-associated muta-
tions and overlapping polymorphisms on treatment-naïve
patients, which affect the transmission of drug resistance
mutant viruses.
Previous evidence suggests that drug resistance muta-
tions may result in significantly decreased replicative fit-
ness and hence transmission efficacy [6]. Thus, we may
expect persons at higher frequency of exposure to non-
treatment-naïve viruses to be at higher risk of receiving
drug resistant strains than those persons under lower
frequency of exposure. In China, one such risk group
with particularly high frequency of HIV-1 exposure is men
who have sex with men (MSM). MSM in China typically
have multiple sexual partners, low rates of condom usage,
and low rates of HIV screening [7,8]. As well, they are a
rapidly expanding high risk population for HIV transmis-
sion: the proportion of all reported cases of HIV infection
in China with history of MSM sex has increased from
2.5% in 2006 to 13.7% in 2011 [9]. It is therefore important
to examine TDR among MSM in China.
Our study focuses on Beijing, where the proportion of
MSM carrying HIV has increased rapidly from 3.1% in
2002 [10] to 4.8% in 2006 [11]. The proportion of MSM
among newly HIV diagnosed cases was 70.7% in 2012
[12], much higher than the corresponding rates in other
cities in China [13-15]. Although several studies have re-
ported TDR among ART-naïve MSM in Beijing [11,16,17],
there lacks a systematic analysis on TDR rates over time
and the co-variation of TDR-associated mutations. Thus,
we performed a comprehensive genetic characterization of
HIV-1 strains prevalent in MSM in Beijing from 2011 to




A total of 262 HIV-1 positive individuals were randomly
recruited from 2011 to 2013 at voluntary counseling and
testing sites (VCT) in Beijing Chaoyang District Center
for Disease Control and Prevention, following three cri-
teria: having had history of MSM sex, being ART-naïve
and newly diagnosed. This study was approved by the
Institutional Research Ethics Community, China Chaoyang
CDC, and all subjects signed informed consent forms prior
to blood collection. Epidemiological data was collected by
trained interviewers. HIV-1 infection status was determined
by an enzyme immunoassay (ELISA, Wantai, China) and
confirmed by Western blot assay (HIV BLOT 2.2, MP
Diagnostics, Singapore). Blood plasma was separated and
stored at −70°C prior to genetic analysis.
HIV-1 RNA extraction, amplification and sequencing
Viral RNA was extracted from 200 μl EDTA-anticoagulated
plasma using a QIAamp viral RNA kit (Qiagen Inc.,
Germany) according to the manufacturer’s instructions.
The HIV-1 pol gene (1,197 bp length), containing the full-
length protease (PR) gene and the first 300 codons of the
reverse transcriptase (RT) gene, were amplified and se-
quenced, using an in-house drug resistance genotyping
method as previously described [18]. The target sequence
was amplified with One Step Reverse Transcription PCR
reagents (Qiagen Inc., Germany) using primers listed in
Table 1. Amplification steps were as follows: reverse tran-
scription at 50°C for 30 min, pre-denaturation at 94°C for
5 min, 30 cycles of denaturation at 94°C for 30 s, annealing
at 55°C for 30 s, extension at 72°C for 2.5 min, and an add-
itional extension at 72°C for 10 min. Nested PCR was per-
formed using Taq PCRmaster mix (Qiagen Inc., Germany)
with primers in Table 1. The cycling conditions were: pre-
denaturation at 94°C for 5 min, 30 cycles of denaturation at
94°C for 30 s, annealing at 63°C for 30 s, extension at 72°C
2.5 min, and an additional extension at 72°C for 10 min.
PCR products were visualized by 1% agarose gel electro-
phoresis and sequenced using ABI 3730xl Automated DNA
Analyzer (Applied Biosystems, Foster City, CA). Each step
was carried out with negative controls.
Phylogenetic analysis
All assembled sequences were submitted to the Los Alamos
National Laboratory HIV Sequence Database (http://www.
hiv.lanl.gov/content/index) to determine HIV genotype,
which were further confirmed by phylogenetic analysis
using standard reference sequences representing subtypes
A–D, F–H, J, K, CRF01_AE, CRF07_BC, and CRF08_BC
(www.hiv.lanl.gov). DNA alignment was performed by the
Clustal W method using MEGA5 [19], followed by manual
adjustment. Phylogenetic analysis was also conducted with
MEGA5 using neighbor-joining trees under a Kimura 2-
parameter model and tested by the bootstrap method with
1,000 replicates.
Drug resistance analysis
Sample pol gene sequences were compared to a consen-
sus sequence using HIV db software (Stanford HIV Drug
Resistance Database, http://hivdb.stanford.edu, version
7.0) to detect drug resistance mutations, including major
and minor protease inhibitor (PI) resistance mutations,
nucleoside reverse transcriptase inhibitor (NRTI), and
non-nucleoside reverse transcriptase inhibitor (NNRTI)
resistance mutations.
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Co-variation analysis between TDR-associated mutations
and positively selected mutations
We analyzed co-variation between TDR-associated mu-
tations and positive selected mutation using the Cor-
Mut package [20]. Briefly, the procedure was: positively
selected mutations were identified using selection pres-
sure (Ka/Ks ratio) based method [21,22], in which a Ka/
Ks value of >1 indicates a positive selection. Log odds
(LOD) confidence score was used to measure the sig-
nificance of selection pressure (cut off > = 2). The
05GX001 strain (subtype CRF01_AE) was used as a ref-
erence when performing the computation. The Jaccard
similarity coefficient was used to measure the co-
variation between TDR mutations and positively se-
lected mutations. Fisher’s exact test was used to check
the significance of co-variation. False discovery rate was
controlled using the Benjamini and Hochberg proced-




Among 262 HIV-1 positive samples, the pol genes of 223
samples (85.11%) were successfully amplified and se-
quenced. The mean age of the 223 patients was 30.3
(range: 17–64). 75.3% of subjects were never married,
21.5% were married, and 3.1% were divorced or widowed.
More than two-thirds of participants (69.5%) had received
college-level or higher education degree. The basic demo-
graphic characteristics are shown in Table 2.
HIV-1 genetic characteristics
Phylogenetic analysis of the amplified pol gene regions
(1197 bp) showed that the samples were generally tightly
clustered within their respective subtypes (Figure 1).
Their genotype distribution was as follows: 135 cases
(60.5%) were subtype CRF01_AE, 62 cases (27.8%) were
subtype CRF07_BC, 22 cases (9.9%) were subtype B, two
were CRF01B, one was CRF55_01B, and one was
CRF08_BC (Table 2). There was no significant difference
in HIV-1 subtype distributions between each year.
Table 1 Primers used in the optimized in-house assay
Primer name Sequence (5,-3,) Location (based on HXB2) Purpose
MAW 26 TTGGAAATGTGGAAAGGAAGGAC 2028-2050 RT-PCR
RT21 CTGTATTTCTGCTATTAAGTCTTTTGATGGG 3509-3539 RT-PCR
PRO-1 CAGAGCCAACAGCCCCACCA 2147-2166 Nested PCR
RT20 CTGCCAGTTCTAGCTCTGCTTC 3441-3462 Nested PCR
MAW26-07BC TGGAAATGTGGAAAAGAAGGAC 2028-2050 RT-PCR
RT21-07BC CTGTATTTCAGCTATCAAGTCTTTTGATGGG 3509-3539 RT-PCR
PRO1-07BC CAGAGCCAACAGCCCCACCA 2147-2166 Nested PCR
RT20-07BC CTGCCAATTCTAATTCTGCTTC 3441-3462 Nested PCR
MAW26-01AE TGGAAATGTGGRAARGAAGGAC 2028-2050 RT-PCR
RT21-01AE GTAYTTCTGCTAYTAAGTCTTTTGATGGG 3511-3539 RT-PCR
PRO1-01AE CAGAGCCAWCAGCCCCACCA 2147-2166 Nested PCR
RT20-01AE CTGCCAAYTCTAATTCTGCTTC 3441-3462 Nested PCR
Table 2 Characteristic and genotypes of study subjects
Total Year
2011 2012 2013
Total 223 21 126 76
Subtype
CRF01_AE 135(60.53%) 12(57.14%) 80(63.49%) 43(56.58%)
CRF07_BC 62(27.80%) 7(33.33%) 31(24.60%) 24(31.58%)
B 22(9.86%) 2(9.53%) 12(9.52%) 8(10.53%)
Others 4(1.79%) 0 3(2.38%) 1(1.32%)
Age
Mean 30.79 27.76 31.35 30.71
≤24 48(21.52%) 7(33.33%) 23(18.26%) 18(23.68%)
25-34 116(52.02%) 11(52.38%) 71(56.35%) 34(44.74%)
35-44 44(19.73%) 3(14.29%) 21(16.67%) 20(26.32%)
≥45 15(6.73%) 0 11(8.73%) 4(5.26%)
Marriage status
Single 168(75.34%) 16(76.19%) 93(73.81%) 59(77.63%)
Married 48(21.52%) 4(19.05%) 30(23.81%) 14(18.42%)
Divorced/
widowed




26(11.66%) 3(14.29%) 15(11.90%) 8(10.53%)
High school 42(18.83%) 4(19.05%) 28(22.22%) 10(13.16%)
College level
and above
155(69.51%) 14(66.67%) 83(65.87%) 58(76.32%)
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Prevalence of transmitted drug resistant variants
Amplified gene regions were assessed for TDR-associated
mutations through the Stanford HIV Drug Resistance
Database. Mutations were classified and summarized ac-
cording to their ability of conferring resistance to PI,
NRTI, or NNRTI drug classes. Among our samples, 25.6%
(57/223) had TDR-associated mutations, including 16.1%
(36/223) for PI mutations, 0.9% (2/223) for NRTI muta-
tions, and 9.0% (20/223) for NNRTI mutations. PI muta-
tions included L10I/V (7.2%, 16/223) and A71L/T/V
(6.3%, 14/223), with relatively high frequency; NRTI muta-
tions, included L74I (0.45%, 1/223) and V75L (0.45%,
1/223); and the most frequent NNRTI mutation was
V179D/E (5.4%, 12/223). Among these detected
mutations, only L74I, M46L, G190E and E138G may
result in drug resistance directly. Most of these muta-
tions only conferred potential drug resistance. The de-
tailed frequency of the mutations was shown in Table 3.
Only six (2.7%) samples carried mutations conferring
known levels of drug resistance, with 1.35% (3/223)
against PIs (nelfinavir), 0.45% (1/223) against NRTIs (aba-
cavir, didanosine), and 0.90% (2/223) against NNRTIs (efa-
virenz, etravirine, nevirapine, riplivirine).
The type and frequency of TDR-associated mutations
were different among different HIV-1 subtypes. The pro-
portion of TDR-associated mutations was 23.7% (32/135)
among CRF01_AE recombinant strains, the most frequent
mutations being L10I/V and V179D/E. Among CRF07_BC
Figure 1 Phylogenetic trees of HIV-1 pol genes were constructed using MEGA 5 based on neighbour-joining methods. The samples’
sequences and reference HIV-1 subtypes (subtypes A–D, F–H, J, K, CRF01_AE, CRF07_BC, CRF08_BC, and group O) available in the Los Alamos
database were aligned using CLUSTAL W with minor manual adjustments. The statistical robustness of the neighbour-joining tree and reliability
of the branching patterns were confirmed by bootstrapping (1000 replicates). The trees were midpoint rooted. Values on the branches represent
the percentage of 500 bootstrap replicates.
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Table 3 HIV TDR-associated mutations identified among different subtypes/year in treatment-naïve Beijing MSM
PI PI mutations NRTI NRTI mutations NNRTI NNRTI mutations Total
Subtype
CRF01_AE 14.07% (19/135) L10I/V(14/19) V11I(2/19) L33F(2/19)
M46L(2/19) A71L(1/19)
1.48% (2/135) L74I(1/2) V75L(1/2) 8.15% (11/135) V106I(1/11) V179D/E(9/11) G190E(1/11) 23.70% (32/135)
CRF07_BC 19.35% (12/62) L10I(1/12) L33I(1/12) Q58E(2/12) A71T/V(8/12) 0 — 1.61% (1/62) E138G(1/1) 20.97% (13/62)
Subtype B 22.72% (5/22) L10I(1/5) A71T/V(5/5) 0 — 31.81% (7/22) V106I(5/7) , V179E(2/7) 54.54% (12/22)
Year
2011 4.77% (1/21) L10I(1/1) 0 — 9.52% (2/21) V106I(2/2) 14.29% (3/21)
2012 17.24% (22/126) L10I/V(8/22) V11I(2/22) L33I/F(3/22)
M46L(2/22) Q58E(1/22) A71T/V(6/22)
2.63% (2/126) L74I(1/2),V75L(1/2) 11.1% (14/126) V106I(4/14) E138G(1/14)
V179D/E(8/14) G190E(1/14)
29.37% (37/126)
2013 17.11% (13/76) L10I/V(5/13) Q58E(1/13) A71T/V(8/22) 0 — 5.26% (4/76) V179D(4/4) 22.37% (17/76)
Total 16.14% (36/223) 0.89% (2/223) 8.52% (19/223) 25.56% (57/223)



















recombinant strains, 21.0% (13/62) had TDR-associated
mutations, A71T/V being the most frequent. Among sub-
type B, 54.5% (12/22) had TDR-associated mutations,
A71T/V and V106I being the most frequent. Detailed in-
formation is summarized in Table 3.
Of note, the distribution of TDR-associated mutations
differed by sampling year (Table 3). In 2011, 14.2% (3/21)
had TDR-associated mutations, while the latter two years
saw rates that were more than two times as high, with
29.4% (37/126) in 2012 and 22.4% (17/76) in 2013.
Co-variation between transmitted drug resistance
and polymorphisms
Co-variation analysis was performed to determine muta-
tions or polymorphisms that were positively selected in
association with TDR-associated mutations (Table 4).
Eight mutation pairs with significant co-variation were
identified in the RT region for CRF01_AE strains between
the V179D/E TDR-associated mutation and seven overlap-
ping polymorphisms. No significant mutation pair was
identified for the PR region and for other subtypes.
Discussion
In this study, we analyzed the HIV-1 pol gene sequences
of 223 ART treatment-naïve MSM in Beijing diagnosed
from 2011 to 2013. The genotype CRF01_AE accounted
for 60.5%, followed by CRF07_BC (27.8%), subtype B
(9.9%), and others. Fifty-seven samples had at least one
TDR-associated mutation, mainly including L10I/V
(6.3%), A71L/T/V (6.3%), V179D/E (5.4%), and V106I
(2.7%), with different distributions of TDR-associated
mutations by different HIV-1 subtypes and by sample
year. Moreover, eight significant co-variation pairs were
found between TDR-associated mutations (V179D/E)
and seven overlapping polymorphisms in subtype
CRF01_AE. This analysis consists the most comprehen-
sive genetic characterization to date on HIV-1 TDR as-
sociated mutations prevalent among MSM in China.
The proportion of samples with TDR-associated muta-
tions over the sample period was determined to be 25.6%.
The mutations frequency rose from 14.3% in 2011 to
29.4% in 2012 and 22.4% in 2013. In addition, the distribu-
tion of mutations sites in 2011 was simpler compared with
2012 and 2013. This indicated that TDR-associated muta-
tions may be becoming increasingly common and com-
plex among Beijing MSM over the last several years.
Although most of these mutations only conferred poten-
tial drug resistance, TDR-associated mutations often con-
fer disadvantage in replicative fitness to the virus. A high
prevalence and increasingly complex patterns of TDR-
associated mutations suggests a generally high frequency
of exposure in the treatment-naïve patients to diverse
sources of viral strains. Thus, TDR-associated mutations
in Beijing MSM may serve as evidence for prevalent high
risk behavior such as repeated unprotected exposure to
multiple sexual partners.
The largest proportion of the HIV-1 strains among our
samples belonged to the CRF01_AE genotype (60.5%),
followed by CRF07_BC (27.8%) and subtype B (9.9%), and
the distribution of HIV-1 subtypes was relatively stable
from 2011 to 2013. This differed from previous reports on
Beijing MSM from 2005, which saw higher prevalence of
subtype B and lower prevalence of CRF01_AE and
CRF07_BC [16]. In the study performed by Li et al. from
2007 to 2010 [17], the proportion of subtype CRF01_AE,
B, and CRF07_BC were 56.0%, 30.8%, and 12.6%, respect-
ively. Comparing to previous reports, the ratio of subtype
B shows a tendency to drop, while the proportions of
CRF01_AE and CRF07_BC are continuously on the rise in
MSM population in Beijing. Historically, CRF01_AE was
strongly associated with sexual transmission routes [23],
while CRF07_BC was associated with intravenous drug
user populations in China [24,25]. It is likely that the in-
crease in CRF07_BC prevalence among MSM was linked
with transmission among drug users [26].
We found unequal distributions of mutations in the
different genotypes, with subtype B having a higher
rate (54.5%) of TDR-associated mutations than in
CRF07_BC and CRF01_AE. This observation coincides
with results from a study among Thai patients, in
which multivariate analysis showed that HIV-1 subtype
B had a higher rate of drug resistance-associated muta-
tions [27]. On the other hand, TDR-associated muta-
tions among CRF01_AE strains showed a diversifying
trend. Nonetheless, the most frequent mutations L10I/V
and V179D/E appeared to be conserved; the latter was
found in 9 out of 11 CRF01_AE strains with drug resist-
ance mutations to NNRTI drugs.
The relative prevalence of V179D/E bears further re-
mark. In a previous study, Archer et al. found that V179D
(a NNRTI resistance mutation) significantly reduced the
replication capacity of HIV-1 [28]. Here, our co-variation
Table 4 Co-variation pairs between overlapping






P value P value
(adjusted)
V179D R238K 0.19047619 0.003425851 0.052072937
V179D A272P 0.125 0.020837895 0.197960003
V179E T11K 0.07894737 0.020123086 0.197960003
V179E I173K 0.08333333 0.01703163 0.197960003
V179E K174Q 0.14285714 0.003172559 0.052072937
V179E S207Q 1 2.39E-06 0.000181289
V179E S211K 0.42857143 8.35E-05 0.003172559
V179E R238K 0.15789474 0.002311436 0.052072937
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analysis showed that V179D/E was significantly associated
with seven polymorphisms in the HIV-1 CRF01_AE geno-
type. These polymorphisms may serve to compensate the
replication disadvantage of V179D/E, allowing this TDR-
associated mutation to be propagated in treatment-naïve
patients [5]. In another study by our team, we had ap-
plied the CorMut algorithm to investigate the associ-
ation between drug resistance and compensatory
mutations, and demonstrated that K101Q, H221Y, and
T139K can enhance K103N/Y181C/G190A-associated
NNRTI-resistance among CRF07_BC in vitro [29]. Cer-
tainly, further study is needed to determine how the
V179D/E-associated polymorphisms affect the replication
fitness of CRF01_AE HIV-1 strains.
However, there are some insufficiency still exists in
our study. First, the study patients were newly diag-
nosed, but we can’t confirm the time of initial infection.
Some TDR-associated mutations have been missing
during this period. Another limitation of the study is re-
lated to the use of population sequencing strategy. Such
a conventional genotyping technique does not allow for
the detection of clinically important minority variants
with TDR-associated mutations [30]. Despite some limi-
tations, current study may facilitate the tracking of
TDR-associated mutations, and should provide a reli-
able data on prevalence of the TDR-associated muta-
tions among MSM in Beijing.
Conclusions
Our work comprehensively characterized HIV-1 strains
prevalent among treatment-naïve MSM in Beijing from
2011 to 2013, including subtype analysis, TDR-associated
mutations, and co-variation of potential compensatory
mutations. TDR mutation rate remains low, but the rate
of TDR-associated mutations is high. There are significant
co-variation pairs between TDR-associated mutations
(V179D/E) and seven overlapping polymorphisms among
subtype CRF01_AE. These findings enhance our under-
standing of TDR and evolution of HIV-1 among Chinese
MSM, and suggest that high risk behavior patterns that fa-
cilitate the transmission of drug resistant HIV strains re-
main highly prevalent, requiring stronger prevention and
control efforts.
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